H.C. Wainwright lowered the firm’s price target on Checkpoint Therapeutics to $20 from $34 and keeps a Buy rating on the shares following the Q2 report. The analyst cites dilution from recent equity raises for the target drop. The firm remains confident that cosibelimab “has a very strong chance” of approval, moving into commercialization stages, and should be added to the market soon after.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CKPT:
- Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
- Checkpoint announces FDA acceptance of BLA resubmission for cosibelimab
- Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
- Biotech Alert: Searches spiking for these stocks today
- Checkpoint Therapeutics, GC Cell advance collaborative cancer research